NCT02365649View on ClinicalTrials.gov

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

March 17, 2015

Primary Completion Date

November 25, 2016

Study Completion Date

August 3, 2017

Conditions
Crohn's Disease
Interventions
DRUG

Placebo

Oral Dosing

DRUG

ABT-494

Oral Dosing

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY